An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma - DIM-95031-002

Servier Affaires Medicales0 个研究点目标入组 109 人开始时间: 2022年10月11日最近更新: 2024年7月22日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Servier Affaires Medicales
入组人数: 109

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•1. Be =18 years of age, 10. Be able to understand and willing to sign the informed consent form (ICF) and to comply with the study procedures., 11. Willingness to comply with contraception guidelines of this study., 2. Have a histopathological diagnosis of CCA consistent with nonresectable or metastatic CCA and are not eligible for curative-intent resection, transplantation, or ablative therapies, 3. Have documented IDH1 R132C, R132L, R132G, R132H, or R132S gene-mutated disease based on a local validated biomolecular profiling method, 4. Have documented locally advanced or metastatic CCA following at least 1 prior line of systemic therapy, 5. Have an ECOG PS score of 0 or 1, 6. Have recovered from toxicities associated with prior anticancer therapy to baseline or have stabilized under medical management, 7. Have adequate bone marrow function as described in the protocol., 8. Have adequate hepatic function as described in the protocol., 9. Have adequate renal function as described in the protocol.

排除标准

•1. Received a prior IDH1 inhibitor, 10. Are taking known strong cytochrome P450 (CYP) 3A4 inducers or inhibitors or sensitive CYP3A4 substrate medications, unless they can be transferred to other medications., 11. Are taking P-glycoprotein (P-gp) transporter-sensitive substrate medications or inhibitors unless they can be transferred to other medications., 12. Have an active infection requiring systemic anti-infective therapy or with an unexplained fever >38.5°C within 7 days of Day 1., 13. Have any known hypersensitivity to any of the components of ivosidenib, 14. Have significant active cardiac disease within 6 months prior to the start of study treatment., 15. Have known active hepatitis B (HBV) or hepatitis C (HCV) infections, known positive human immunodeficiency virus (HIV) antibody results, or acquired immunodeficiency syndrome (AIDS) related illness., 16. Have any gastrointestinal medical condition which would limit ingestion or gastrointestinal absorption according to investigator’s judgment, 2. Had a prior transplantation, 3. Received systemic anticancer therapy <2 weeks prior to first dose of study treatment on C1D1, immune based anticancer therapy <4 weeks prior to C1D1, or an investigational agent <5 half-lives of this agent prior to C1D1, 4. Received radiotherapy to metastatic sites of disease <2 weeks prior to C1D1, 5. Underwent hepatic radiation, chemoembolization, and radiofrequency ablation <4 weeks prior to C1D1, 6. Have known symptomatic brain metastases requiring steroids., 7. Have a history of another primary cancer, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid or liquid tumor with no known active disease present that, in the opinion of the Investigator, will not affect patient outcome in the setting of current CCA diagnosis., 8. Underwent major surgery <4 weeks prior to C1D1 or have not recovered from post-surgery toxicities, 9. Are pregnant or breastfeeding

研究者

发起方

Servier Affaires Medicales

相似试验

招募中

1 期

An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinomaocally Advanced or Metastatic CholangiocarcinomaMedDRA version: 20.0Level: PTClassification code: 10008593Term: Cholangiocarcinoma Class: 100000004864

CTIS2022-501463-40-01Servier Affaires Medicales246

已完成

2 期

A Phase 1, Open Label, Exploratory Study for the Intra-operative Imaging of Folate Receptor Alpha Positive Ovarian, Lung, Breast Cancer and Parathyroid adenomas using the Tumor Specific Imaging Agent EC17mammacarcinoma / breast cancerparathyroid adenomasprimary non small cell lung carcinoma / lung cancerprimary ovarian carcinoma / ovarian cancer10027655

NL-OMON40272Centre for Human Drug Research75

进行中（未招募）

不适用

Detection of ovarian and lung cancer during an operation with the fluorescent agent 'EC17'primary ovarian carcinoma and primary non small cell lung carcinoma

EUCTR2013-004089-33-NLCentre for Human Drug Research

进行中（未招募）

1 期

CTIS2023-510190-34-00GlaxoSmithKline Biologicals1,450

进行中（未招募）

1 期

Immunobridging study of V501 in Chinese girls and young wome

EUCTR2023-001144-29-Outside-EU/EEAMerck Sharp & Dohme LLC